Ultragenyx Pharmaceutical (NASDAQ:RARE) Issues Earnings Results

Ultragenyx Pharmaceutical (NASDAQ:RARE) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07), Zacks reports. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE traded up $0.09 during trading hours on Thursday, hitting $43.52. The company’s stock had a trading volume of 784,283 shares, compared to its average volume of 897,107. The business has a 50-day simple moving average of $43.81 and a 200-day simple moving average of $49.59. The stock has a market cap of $4.02 billion, a price-to-earnings ratio of -6.73 and a beta of 0.60. Ultragenyx Pharmaceutical has a 12 month low of $37.02 and a 12 month high of $60.37.

Insiders Place Their Bets

In related news, CEO Emil D. Kakkis sold 11,727 shares of the stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the transaction, the chief executive officer now directly owns 2,183,985 shares of the company’s stock, valued at $92,229,686.55. This represents a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.80% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the subject of a number of recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. JPMorgan Chase & Co. cut their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. TD Cowen raised their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 22nd. Finally, Piper Sandler lifted their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $92.43.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.